Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study (Q73093100)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

title

Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

1 reference

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

Maurizio D'Incalci

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

author name string

O Pagani

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

C Sessa

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

F Nolè

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

D Crivellari

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

D Lombardi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

B Thürlimann

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

D Hess

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

M Borner

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

J Bauer

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

G Martinelli

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

R Graffeo

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

A Goldhirsch

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

publication date

1 August 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

985-991

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens

1 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008392927656

7 January 2021

https://api.crossref.org/works/10.1023%2FA%3A1008392927656

1 reference

7 January 2021

Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008392927656

7 January 2021

Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008392927656

7 January 2021

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008392927656

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008392927656

7 January 2021

Management of fever in patients with cancer and treatment-induced neutropenia

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008392927656

7 January 2021

Paclitaxel induces significant changes in epidoxorubicin distribution in mice

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008392927656

7 January 2021

Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008392927656

7 January 2021

NL-FIT: a microcomputer program for non-linear fitting.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008392927656

7 January 2021

Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008392927656

7 January 2021

Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008392927656

7 January 2021

Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008392927656

7 January 2021

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008392927656

7 January 2021

Clinical pharmacokinetics of epirubicin.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008392927656

7 January 2021

Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008392927656

7 January 2021

Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG).

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008392927656

7 January 2021

Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008392927656

7 January 2021

Identifiers

DOI

10.1023/A:1008392927656

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038035%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference